AIM: To determine the prognostic value of microtubule component expression in tumors of patients with carcinomas of unknown primary site (CUP). PATIENTS AND METHODS: Class III beta-tubulin, Delta2-alpha-tubulin and tau protein were examined immunohistochemically in 51 CUP tumors from patients receiving paclitaxel and compared with their response to treatment. RESULTS: The overall response rate was 18.4% among 49 evaluable patients. Delta2-alpha-Tubulin and tau were not correlated with response or patient outcome. High class III beta-tubulin expression was correlated with both resistance to chemotherapy and shorter overall survival, while there was no relation with progression-free survival. In multivariate analysis taking into account clinical factors, class III beta-tubulin expression was independently correlated with overall survival. CONCLUSION: These findings show that in tumor cells a high level of expression of class III beta-tubulin, but not Delta2-alpha-tubulin or tau, is associated with resistance to paclitaxel and a poor prognosis in CUP patients receiving paclitaxel.
AIM: To determine the prognostic value of microtubule component expression in tumors of patients with carcinomas of unknown primary site (CUP). PATIENTS AND METHODS: Class III beta-tubulin, Delta2-alpha-tubulin and tau protein were examined immunohistochemically in 51 CUP tumors from patients receiving paclitaxel and compared with their response to treatment. RESULTS: The overall response rate was 18.4% among 49 evaluable patients. Delta2-alpha-Tubulin and tau were not correlated with response or patient outcome. High class III beta-tubulin expression was correlated with both resistance to chemotherapy and shorter overall survival, while there was no relation with progression-free survival. In multivariate analysis taking into account clinical factors, class III beta-tubulin expression was independently correlated with overall survival. CONCLUSION: These findings show that in tumor cells a high level of expression of class III beta-tubulin, but not Delta2-alpha-tubulin or tau, is associated with resistance to paclitaxel and a poor prognosis in CUP patients receiving paclitaxel.
Authors: Susanna B Park; John B Kwok; Clement T Loy; Michael L Friedlander; Cindy S-Y Lin; Arun V Krishnan; Craig R Lewis; Matthew C Kiernan Journal: BMC Cancer Date: 2014-12-22 Impact factor: 4.430
Authors: Daria M Potashnikova; Aleena A Saidova; Anna V Tvorogova; Eugene V Sheval; Ivan A Vorobjev Journal: Front Pharmacol Date: 2019-04-24 Impact factor: 5.810